The influence of amplification of ERBB2 is on the percent of relapse of inflammatory breast cancer after the combined treatment
Smolanka I.I.1, Movchan O.V.1, Lyashenko A.O. 1, Ivankova O.M. 1, Ваgmut I.Yu.2
- 1National Cancer Institute of Ukraine, Kyiv
- 2Kharkiv Medical Academy of Postgraduate education, Kharkiv, Ukraine
Summary. We consider the molecular mechanisms related to inflammation critical a component in advancement of inflammatory breast cancer, that’s driving reason for passing among women. A relapse remains one of the foremost serious issues for patients with inflammatory breast cancer after the combined treatment. Immovability to antitumoral arrangements takes put at the level of texture through the highlights of the utilized for setting microenvironment amid cancer penetration. 60 patients for period from 2018 for 2020 inspected — a 1 group (30 patients): with the confirmed mutation of Her2/neu gene (amplification of ERBB2 (3+)), with inflammatory breast cancer after the conducted combined treatment (surgery with neoadjuvant chemotherapy). There were no amplification of ERBB2 (3+) in 30 patients with inflammatory breast cancer (2 group). Patients have amplification of ERBB2 with the inflammatory carcinoma, with a nasty prognosis in relation to development of relapse of disease. Invasion activity of tumor cells with amplification of ERBB2 for the inflammatory carcinoma are higher, than without amplification of ERBB2, that it’s well-proven the indexes of middle mark of expression of CD68, Stabilin-1, YKL-39, SI-CLP within the tumor cell culture. There are discovered the upper closeness of CD3+ (10 time), CD19 + (4 times) lymphocytes and lower closeness CD3+, CD8+ (1.5 times) and CD16/56+ (2 times) lymphocytes with amplification of ERBB2 in comparing to the indexes for patients without amplification of ERBB2 (р <0,05). Relapse of disease amid first two years after treatment was identified in (60± 8,9)% patients of 1 group and in 26.7±8.1% patients of 2 group.
Leave a comment